A fully absorbable prosthesis (1) for the repair of damaged ligaments and/or tendons in the form of a multilayer spiral roll comprising the following spiral layers: a foraminous layer (2) of a synthetic bioabsorbable material; a bioabsorbable film (3); and a layer (4) of a bioabsorbable biopolymer sponge. The invention also provides a method of making such a prosthesis, comprising the steps of: providing a laminate of a foraminous layer of bioabsorbable material and a bioabsorbable film; coating the laminate with a layer of an aqueous gel comprising a bioabsorbable polymer; rolling up the laminate and the gel layer into a spiral roll, followed by drying the gel to form a layer of bioabsorbable sponge. The foraminous layer (2) preferably comprises a synthetic bioabsorbable polymer having high tensile strength. The bioabsorbable film (3) and sponge layer (4) preferably comprise a chemotactic biopolymer such as collagen.

Patent
   5595621
Priority
Sep 29 1993
Filed
Jun 07 1995
Issued
Jan 21 1997
Expiry
Sep 29 2014
Assg.orig
Entity
Large
134
20
all paid
1. A method of making a bioabsorbable prosthesis for use in surgical repair of a damaged ligament or tendon, the method comprising the steps of:
providing a laminate of a foraminous layer of bioabsorbable material and a bioabsorbable film; coating the laminate with a layer of an aqueous gel comprising a bioabsorbable polymer; rolling up the laminate and the gel layer into a spiral roll, followed by drying the gel to form a layer of bioabsorbable sponge.
2. A method of making a bioabsorbable prosthesis according to claim 1, wherein the said step of rolling up comprises rolling up through between 2 and 6 complete 360° revolutions.
3. A method of making a bioabsorbable prosthesis according to claim 1, wherein the step of providing a bioabsorbable film comprises the steps of:
providing a layer of an aqueous solution or suspension of bioabsorbable material, and
drying the said layer.
4. A method of making a bioabsorbable prosthesis according to claim 3, wherein the said layer of an aqueous solution or suspension of the bioabsorbable material is coated onto the foraminous layer of a synthetic bioabsorbable material, or wherein the layer of a synthetic bioabsorbable material is immersed in the layer of an aqueous solution or suspension of bioabsorbable material.
5. A method of making a bioabsorbable prosthesis according to claim 3, further comprising the steps of emulsifying a bioabsorbable oil in said aqueous solution or suspension of bioabsorbable material.
6. A method of making a bioabsorbable prosthesis according to claim 1, wherein the aqueous gel comprises acid-swollen collagen.
7. A method of making a bioabsorbable prosthesis according to claim 1, further comprising the step of emulsifying a bioabsorbable oil in the aqueous gel.
8. A method of making a bioabsorbable prosthesis according to claim 1, wherein the step of drying the gel to form a bioabsorbable sponge comprises the steps of freezing the gel, followed by freeze-drying the gel by evaporation of water under reduced pressure.
9. A method of making a bioabsorbable prosthesis according to claim 1, wherein the step of drying the gel to form a bioabsorbable sponge comprises the steps of freezing the gel, followed by solvent drying the frozen gel.

This is a division of application Ser. No. 08/314,986, filed Sep. 29, 1994, which is hereby incorporated by reference, now U.S. Pat. No. 5,514,181.

The present invention relates to absorbable structures for use as temporary prostheses in the repair of damaged ligaments and/or tendons.

Damage to ligaments and/or tendons is a frequent occurrence, particularly as a consequence of violent exercise or contact sports. An especially common and difficult to treat sports injury is tearing of the anterior cruciate ligament (ACL) of the knee.

Various approaches have been tried to restore the function of torn tendons or ligaments. The simplest approach is simply to suture together the torn ends of the ligament or tendon. However, the healing rate of ligaments or tendons sutured in this way is extremely slow, and even after healing is complete the strength of the ligament or tendon is substantially reduced. Moreover, the scar tissue tends to propagate into surrounding tissues causing discomfort and loss of mobility.

In another approach, the ligament or tendon is replaced by a permanent prosthesis of biocompatible but non-resorbable material, such as Dacron®, PTFE or polypropylene. A favoured permanent prosthesis consists of bundles of carbon fibers, optionally coated with a biocompatible polymer. However, none of the permanent prostheses has proved to be sufficiently durable to replace a ligament or tendon for the life of a user. In particular, it has been found that the carbon-fiber based prostheses tend to crack after 12-18 months of use, thereby releasing carbon particles that can cause severe inflammatory reactions and even arthritis.

A further approach to the repair of damaged tendons or ligaments has been to implant a temporary, biodegradable prosthesis that can stabilize the tendon or ligament and provide a framework for healing of the tendon or ligament while gradually being absorbed into the body. Accordingly, the requirements for such a temporary prosthesis include: high tensile strength to restore tendon or ligament function, slow but complete bioabsorption in situ, low antigenicity, and a directional (uniaxial) structure that promotes formation of strong, well-oriented scar tissue by directional ingrowth of fibroblasts from the undamaged ends of the ligament or tendon.

WO85/00511 describes a collagen-based material for regeneration of ligaments and/or tendons. The material is formed from strands of collagen that have been cross-linked with glutaraldehyde to increase their tensile strength. The collagen strands are provided in the form of a suitable weave with sufficient space between the strands to function as a "scaffold" through which ligament fibroblasts can propagate. A sheet of the collagen weave may be rolled up to form a cylinder of spiral cross-section which positioned between ends of e.g. a torn anterior crucia. ligament, the ends of the cylinder being sutured to the undamaged ends of the ligament. The joint is immobilized, and healing of the ligament is said to be completed in as little as three weeks.

Similarly, U.S. Pat. No. 5,171,273 describes absorbable ligament or tendon prostheses formed from high-strength collagen fibers. The high-strength collagen fibers are formed by the steps of: dissolving type I collagen in dilute HCl, extruding the solution into a special buffer bath to reconstitute the collagen fibers, and cross-linking the reconstituted fibers using glutaraldehyde or a combination of severe dehydration and treatment with cyanamide. The fibers are woven, twisted or braided together to form the absorbable ligament and/or tendon prostheses.

A drawback of tendon and/or ligament prostheses that are formed solely from collagen is that the collagen loses its tensile strength rapidly in vivo, even when cross-linked as described above. This characteristic of collagen is incompatible with the relatively long healing times required for repair of ligaments or tendons.

WO88/06872 describes an implantable prosthesis for the repair of tendons or ligaments, characterized by a structure of a bioabsorbable material other than proteins or polypeptides or derivatives thereof. The structure exhibits longitudinal grooves or channels intended to serve as initial propagation guides for new fibrous tissue. For example, the prosthesis may consist of a plurality of concentric tubes of a synthetic bioabsorbable polymer, such as a copolymer of lactic and glycolic acids, polyhydroxy butyric acid or the like. The interstices between the tubes provide the longitudinal channels for tissue ingrowth.

EP-A-0241252 describes an absorbable ligament or tendon prosthesis formed from melt-spun filaments of a special end-capped lactide polymer having exceptionally high tensile strength. The filaments are plied, twisted or braided to form the ligament or tendon prosthesis. The twist or braid provides a relatively open structure which is geometrically capable of allowing natural tissue to be deposited along the filaments and develop natural tendon or ligamentous tissue.

A drawback of the above absorbable prostheses based solely on synthetic, non-collagenous polymers is that the prostheses cannot exhibit the beneficial wound-healing properties of biopolymers such as collagen. It is well known that wound-healing cells such as fibroblasts have a special affinity for collagen and certain other biopolymers. This property is termed the chemotactic effect of collagen.

A further drawback of all previous absorbable tendon and/or ligament prostheses is that the porosity of the prostheses to cellular invasion by fibroblasts is not optimised. It has been determined that a pore or channel size in the range 50-250 μm is preferred for promoting cellular invasion, but hitherto the implant materials have not provided a controlled porosity in this range.

Accordingly, it is an object of the present invention to provide fully bioabsorbable ligament and/or tendon prostheses that combine high tensile strength, chemotactic properties and optimised porosity for directional cellular invasion and healing.

The present invention provides a bioabsorbable ligament or tendon prosthesis in the form of a multilayered spiral roll comprising the following spiral layers: a foraminous layer of a synthetic bioabsorbable material; a bioabsorbable film, and a layer of a bioabsorbable sponge.

The prostheses according to the present invention are in the form of a multilayered spiral roll, also known as a "Swiss roll" structure. That is to say, the prostheses are formed by rolling up a plurality of overlapping layers into a cylindrical roll. Each of the layers is thereby rolled into a spiral roll that is coaxial with and radially alternating with the other layers.

The spiral roll preferably has a diameter in the range of from 1.2 to 21 mm, more preferably 3.0 to 10.0 mm. The length of the spiral roll is preferably 5 to 80 mm. The spiral roll preferably contains from 2 to 6 complete 360° turns of the spiral.

The chief function of the foraminous layer of a synthetic bioabsorbable material is to provide tensile strength to the prosthesis. The foraminous nature of this layer enhances the flexibility of the prosthesis and allows easy suturing of the prosthesis. Preferably the foraminous layer is a woven, non-woven or knitted mesh.

Preferably, the foraminous layer comprises a polymer or copolymer of lactic acid or glycolic acid, oxidized regenerated cellulose, polydioxanone (PDS), a copolymer of lactic acid and ε-caprolactam, polyhydroxybutyric acid or a copolymer of hydroxybutyric acid and hydroxyvaleric acid. More preferably, the foraminous layer comprises one of the copolymers of lactic acid and glycolic acid sold under the Registered Trade Mark VICRYL, or the oxidized regenerated cellulose sold under the Registered Trade Mark SURGICEL. Most preferably, the foraminous layer comprises the melt-spun polylactide or polylactide/polyglycolide copolymer described in EP-A-0241252.

The foraminous layer does not need to be bonded to either the continuous film or to the sponge layers. However, preferably, the foraminous layer is bonded to one or both of the film or the sponge layer, and more preferably the foraminous layer is actually embedded in one or other of the film or the sponge layer, as described further below.

The maximum thickness of the foraminous layer is preferably in the range 0.02 to 0.3 mm, more preferably 0.04 to 0.1 mm.

The bioabsorbable film is a continuous or substantially continuous layer of bioabsorbable material that serves to block cellular migration in radial directions inside the prosthesis. That is to say, the barrier layer of bioabsorbable film serves to guide cellular migration axially along the prosthesis, resulting in the formation of well oriented and strong replacement tissue. The bioabsorbable film is preferably formed by drying an aqueous solution or suspension comprising a biopolymer such as collagen, a glycosaminoglycan such as hyaluronic acid, or the like. Preferably, the bioabsorbable film contains a bioabsorbable plasticiser. Preferably the plasticiser is a polyhydric alcohol such as glycerol, and preferably it is present in an amount of 5% to 50% w/w.

The biopolymer is preferably cross-linked to reduce the rate at which it is bioabsorbed. Preferred cross-linking agents include aldehydes such as glutaraldehyde, isocyanates and carbodiimides. The biopolymer film preferably also contains oil microdroplets dispersed therein in order further to reduce the rate of bioabsorption. The oil microdroplets may comprise any biocompatible and bioabsorbable oil, such as sunflower seed oil, sesame seed oil or fish oil. Preferably, the oil is present in an amount of 1 to 90% by weight, more preferably 10 to 75% by weight based on the weight of the biopolymer film.

Preferably, the foraminous layer is actually coated with the bioabsorbable film or embedded therein, so that the interstices in the foraminous layer are substantially all filled by the material of the bioabsorbable film. Particularly preferred composite materials comprising a reinforcing mesh embedded in a collagen film are described and claimed in EP-A-0194192.

The thickness of the bioabsorbable film (except when it forms a composite with the foraminous layer) is preferably in the range 0.01-0.1 mm, and more preferably 0.015-0.03 mm.

The layer of a bioabsorbable biopolymer sponge serves as a spacer between the coils of the reinforcing layer and the bioabsorbable film, defining a uniform and directional interstitial channel for cellular invasion. The porosity of the sponge and the chemotactic effect of the biopolymer combine to promote rapid invasion by fibroblasts, resulting in rapid tissue regeneration. Preferably, the sponge comprises collagen, a glycosaminoglycan such as chondroitin sulfate or hyaluronic acid or a mixture of such biopolymers. Preferably, the porosity of the sponge is optimised for maximum cellular ingrowth, implying that at least 80% of the pores have an average pore diameter in the range 50 μm-250 μm. Such relatively small pore sizes can be obtained, for example, by flash freezing of a collagen solution or suspension (resulting in very small ice crystals) followed by freeze drying, as described in WO90/00060. Alternatively or additionally, small pore sizes may be obtained by including a volatile anti-freeze such as ethanol or isopropanol in the gel, preferably in an amount of 5-25% w/v. The presence of the anti-freeze results in the formation of smaller ice crystals on freezing, and hence smaller pores on freeze-drying.

Preferably, the sponge comprises chemotherapeutic agents in addition to the structural biopolymer. For example, the sponge may contain an antiseptic or an antibiotic. Preferably, the sponge contains a wound healing factor such as a growth factor, a cytokine, an alginate, a glycosaminoglycan or an active derivative thereof. The bioabsorbable film may alternatively or additionally contain the same or a different therapeutic agent or agents.

Preferably, the structural biopolymer of the sponge is cross-linked to reduce the rate of bio-absorption of the sponge. Preferably, the structural biopolymer is collagen and the cross-linking agent is one of those described above for the bioabsorbable film. Also preferably, the biopolymer sponge contains preferably 1 to 90% by weight, more preferably 10 to 75% by weight based on the weight of the sponge, of oil microdroplets dispersed therein. The oil may be any biocompatible and biodegradable oil such as sunflower seed oil, sesame seed oil or fish oil. The presence of the oil microdroplets substantially reduces the rate of bioabsorption of the sponge. Furthermore, the oil microdroplets can be used as vehicles for hydrophobic, oleophilic therapeutic agents.

Preferably, the thickness of the sponge layer is in the range 0.5 to 2.5 mm, more preferably 1.0 to 1.5 mm.

Preferably, the sponge layer has embedded therein one or more solid bioabsorbable rods extending longitudinally through part or all of the prosthesis. The rods may be sections of bioabsorbable stuture, preferably collagen suture. The rods enhance the uniaxial directionality of the sponge layer and reduce the rate at which the layer is absorbed in vivo.

The present invention also provides the use of a bioabsorbable prosthesis as described above for the preparation of a surgical implant for the repair of a damaged tendon or ligament.

The present invention further provides a method of making a bioabsorbable prosthesis for use in surgical repair of a damaged ligament or tendon, the method comprising the steps of: providing a laminate of a foraminous layer of bioabsorbable material and a bioabsorbable film; coating the laminate with a layer of an aqueous gel comprising a bioabsorbable polymer; rolling up the laminate and the gel layer into a spiral roll, followed by drying the gel to form a layer of bioabsorbable sponge.

Preferably, the gel is dried to form the bioabsorbable sponge by freezing (preferably flash freezing), followed by freeze-drying by evaporation of water from the gel under reduced pressure. In alternative preferred methods, the gel is frozen or flash-frozen and the frozen gel is then solvent dried by treatment with a hygroscopic solvent such as isopropyl alcohol.

The laminate comprises overlapping layers of the foraminous layer of bioabsorbable material and the bioabsorbable film. Preferably, the laminate comprises a high tensile strength foraminous mesh embedded in a film of a biopolymer such as collagen, as described in EP-A-0194192.

The compositions of the foraminous layer and the bioabsorbable film may be the same or different, and are preferably as defined above for preferred embodiments of the tendon or ligament prostheses of the present invention.

Preferably, the aqueous gel comprises acid-swollen collagen fibers, preferably at a concentration of 0.1%-5% w/v. In preferred methods, fibrous collagen is extracted from bovine corium or tendon and pre-washed to remove the majority of non-collagenous components as described in U.S. Pat. No. 4,614,794 or U.S. Pat. No. 4,320,201. The collagen is then suspended in clean deionised pyrogen-free water and homogenised to a fine fibrous suspension by passage through a homogenising system. Suitable homogenising systems are described in U.S. Pat. No. 4,320,201.

Homogenization is continued until a desired degree of fiber division is achieved. This results in a preferred fiber size in the range 0.01 to 10 mm.

The homogenized collagen is acidified to cause it to swell and form a gel suitable for freeze drying. The acidifying step may use an organic acid such as formic, acetic, propionic, lactic or malonic, or dilute inorganic acids such as hydrochloric acid. Preferably the homogenized collagen suspension is acidified to pH 2 to 6, more preferably pH 3.0 to 4.5.

Chemotherapeutic agents, preferably as described above, may be dispersed in the aqueous gel of the bioabsorbable polymer, preferably in an amount of 0.1% to 50% w/w, based on the dry weight of the sponge. Also preferably, microdroplets of a bioabsorbable oil may be dispersed in the aqueous gel by emulsification at high shear (collagen is an effective emulsifier). Preferably, the oil microdroplets are present in an amount of from 1% to 90% by weight, more preferably 10% to 75%, based on the dry weight of the sponge.

Preferably, the aqueous gel is dried by flash freezing at temperatures below -20°C, followed by freeze drying, preferably as described in WO90/00060. The flash freezing results in smaller ice crystals, and thus provides smaller pores in the freeze-dried sponge. The pore size of the freeze-dried sponge may also be reduced by adding volatile anti-freeze substances such as ethanol or isopropanol to the aqueous gel before it is frozen, since these also will tend to reduce the size of the ice crystals formed on freezing. Preferably, the anti-freeze substance is added in an amount of 5%-25% w/v, based on the volume of the gel.

Preferably, the freeze-drying step is carried out either by evaporating the water (and other volatile components) from the frozen gel under reduced pressure, or by solvent drying, which involves treating the frozen gel with a hygroscopic solvent, such as isopropyl alcohol, to extract the water from the frozen gel. Surprisingly, it has been found that the presence of volatile antifreeze agents such as ethanol or isopropyl alcohol in the frozen gel results in accelerated solvent drying.

Preferably, the laminate with the layer of aqueous gel thereon is rolled up through 2 to 6 complete 360° revolutions prior to drying. The aqueous gel may be prechilled to 0°-5°C prior to the rolling-up step in order to increase the rigidity of the gel and reduce the gel lost by squeezing out of the ends of the roll. Preferably, the rolling-up step is initiated by rolling up about a small diameter bobbin, e.g. a hypodermic needle, which is removed after the rolling up is complete. A small excess of the aqueous gel (up to 50% excess) may be used to compensate for gel lost in the rolling-up step.

In other preferred methods according to the invention, one or more bioabsorbable rods is laid atop the laminate and extending substantially parallel to the axis about which the laminate is to be rolled up. The bioabsorbable rods are preferably sections of bioabsorbable suture, and preferably comprise collagen. The rods help to ensure a uniform thickness for the sponge layer in the dried prosthesis.

In yet other preferred embodiments, the method according to the present invention may further comprise the step of incubating the dried prosthesis in vitro with host cells such as host synovial cells or host fibroblast cells prior to implantation. The cells may even be injected into the body of the prosthesis. After a suitable time to achieve required cellular growth and proliferation in the prosthesis, the structure can be implanted in the body.

A specific embodiment of the tendon or ligament prosthesis of the invention will now be described further, by way of example with reference to the accompanying drawings, in which:

FIG. 1 shows a transverse cross-section through a bioabsorbable prosthesis according to the present invention;

FIG. 2 shows stages in the method of making the bioabsorbable prosthesis of FIG. 1; and

FIG. 3 shows the bioabsorbable prosthesis of FIG. 1 in use to repair a severed ligament.

Referring to FIG. 1, the prosthesis 1 comprises a multilayered spiral roll consisting of a foraminous layer 2 of a synthetic bioabsorbable material, a bioabsorbable film 2 and a layer 3 of bioabsorbable sponge. The foraminous layer 2 is composed of a polylactide/polyglycolide mesh sold under the Registered Trade Mark VICRYL. The bioabsorbable film 3 is composed of Type I collagen fibers cross-linked with hexamethylene diisocyanate. The sponge layer 4 is also formed from Type I collagen fibers cross-linked with hexamethylene diisocyanate.

In use, the prosthesis 1 is used to replace part or all of a damaged ligament or tendon, as shown in FIG. 3. The ends 5, 6 of the prosthesis are sutured to the undamaged ends 7, 8 of the ligament or tendon. Alternatively, one of the ends 5, 6 of the prosthesis may be attached directly onto a bone or into a socket provided in a bone.

FIG. 3 also shows schematically, by means of arrows, the direction of cellular migration and tissue ingrowth into the prosthesis 1 from the undamaged ends 7, 8 of the ligament or tendon. The cells, especially fibroblasts, migrate rapidly into the collagen sponge on account of its porosity and the chemotactic effect of collagen. However, the cell migration is highly directional, since the collagen sponge spiral layer 4 defines a longitudinal channel for cellular migration. Radial cellular migration is blocked by the bioabsorbable film layer 3. The VICRYL mesh layer 2 provides the necessary tensile strength to the prosthesis while retaining sutureability.

Specific embodiments of method of manufacture of prosthesis according to the present invention will now be described further, by way of the following examples:

A prosthesis for a ligament or tendon according to the present invention comprising separate layers of foraminous synthetic bioabsorbable polymer, bioabsorbable film, and bioabsorbable sponge is prepared as follows:

Fibrous collagen, obtained from bovine corium and pre-washed to remove the majority of non-collagenous components as described in U.S. Pat. No. 4,614,794 or U.S. Pat. No. 4,320,201 is suspended in clean deionised pyrogen-free water at 0.45% w/v concentration and homogenised to a fine fibrous suspension by passage through a homogenizing system similar to that described in U.S. Pat. No. 4,320,201. Homogenisation is continued until the collagen fiber size is in the range 0.1-1.0 mm. The suspension is acidified to pH 4.5 with acetic acid to swell the collagen.

To the collagen gel prepared in Step A above glycerol is added as a plasticiser to a final weight of 0.5% w/w and the gel is then spread in a flat tray having a non-stick surface (e.g. PTFE) to a depth of about 2 mm. The gel is then dried in warm air to leave a continuous, flexible film of collagen about 0.02 mm thick.

A piece of VICRYL® polylactide/polyglycolide mesh of rectangular shape and dimensions approximately 20 mm×40 mm×0.1 mm is placed in a flat-bottomed tray. A piece of the collagen film prepared in Step B of identical size and shape is placed atop the VICRYL mesh.

A layer of the collagen gel prepared as in Step A but containing 0.5% w/v collagen solids and 10% w/v isopropanol, and with a final pH of 4.5 is spread approximately 1-2 mm deep across the top surface of the laminate prepared in Step C. The gel is quickly degassed and the laminate with the gel layer thereon is quickly but gently rolled up around one long edge of the rectangular piece. The resulting helical coil is flash frozen as described in WO90/00060 followed by freeze drying to produce the prosthesis. In the resulting collagen sponge layer, at least 80% of the pores have average pore sizes in the range 35 to 250 μm, which is near-optimum for cellular invasion.

A prosthesis for the repair of a ligament or tendon according to the present invention, in which the foraminous synthetic bioabsorbable layer is embedded in the bioabsorbable film is prepared as follows:

First, a collagen slurry is prepared as in Step A of Example 1, and a glycerol plasticiser is added to the slurry as in Step B. A layer of VICRYL mesh is placed in the bottom of a flat tray having a non-stick (e.g. PTFE) surface, and the slurry is then poured over the VICRYL mesh to a depth of about 2 mm, thereby immersing the VICRYL mesh in the collagen slurry. The slurry is then dried in warm air to produce a composite layer of material comprising the VICRYL mesh embedded in a collagen film. The preparation of such composite layers is described in detail in EP-A-0194192.

A rectangular piece of the composite material of dimensions 20 mm×40 mm is then used as the laminate in Step D above to produce the desired prosthesis.

A bioabsorbable prosthesis for the repair of a ligament or tendon having oil microdroplets dispersed in the bioabsorbable film and in the bioabsorbable sponge is prepared as follows:

A collagen slurry is prepared as in step A of Example 1. To this slurry is added sesame seed oil at 50% (as % of the collagen content w/w), and the mixture is homogenized at high shear to emulsify the sesame seed oil. The collagen serves as an effective emulsifier. The remaining steps of the method are carried out as described above for Example 2.

The resulting prosthesis undergoes substantially slower bioabsorption and loss of tensile strength in vivo than the prosthesis produced in Example 2.

The above specific embodiment and examples are intended for the purpose of illustration only. Many other embodiments and methods according to the present invention as defined in the accompanying claims will be apparent to the skilled reader.

Harvey, Wilson, McGregor, James, Light, Nicholas D., Watt, Paul W.

Patent Priority Assignee Title
10005038, Sep 02 2014 Lockheed Martin Corporation Hemodialysis and hemofiltration membranes based upon a two-dimensional membrane material and methods employing same
10017852, Apr 14 2016 Lockheed Martin Corporation Method for treating graphene sheets for large-scale transfer using free-float method
10039647, Jul 07 2007 JMEA Corporation Disk fusion implant
10070948, Jun 27 2008 Sofradim Production Biosynthetic implant for soft tissue repair
10080639, Dec 29 2011 Sofradim Production Prosthesis for inguinal hernia
10118130, Apr 14 2016 Lockheed Martin Corporation Two-dimensional membrane structures having flow passages
10159555, Sep 28 2012 Sofradim Production Packaging for a hernia repair device
10184032, Feb 17 2015 Sofradim Production Method for preparing a chitosan-based matrix comprising a fiber reinforcement member
10201784, Mar 12 2013 Lockheed Martin Corporation Method for forming perforated graphene with uniform aperture size
10203295, Apr 14 2016 Lockheed Martin Corporation Methods for in situ monitoring and control of defect formation or healing
10213283, Jun 07 2013 Sofradim Production Textile-based prosthesis for laparoscopic surgery
10213746, Apr 14 2016 Lockheed Martin Corporation Selective interfacial mitigation of graphene defects
10327882, Sep 29 2014 Sofradim Production Whale concept—folding mesh for TIPP procedure for inguinal hernia
10342652, Dec 29 2011 Sofradim Production Barbed prosthetic knit and hernia repair mesh made therefrom as well as process for making said prosthetic knit
10363690, Aug 02 2012 Sofradim Production Method for preparing a chitosan-based porous layer
10368971, Dec 03 2007 Sofradim Production Implant for parastomal hernia
10376845, Apr 14 2016 Lockheed Martin Corporation Membranes with tunable selectivity
10405960, Jun 07 2013 Sofradim Production Textile-based prothesis for laparoscopic surgery
10418143, Aug 05 2015 Lockheed Martin Corporation Perforatable sheets of graphene-based material
10471199, Jun 21 2013 Lockheed Martin Corporation Graphene-based filter for isolating a substance from blood
10472750, Mar 16 2011 Sofradim Production Prosthesis comprising a three-dimensional and openworked knit
10493180, Sep 05 2008 Synovis Life Technologies, Inc. Device for soft tissue repair or replacement
10500546, Jan 31 2014 Lockheed Martin Corporation Processes for forming composite structures with a two-dimensional material using a porous, non-sacrificial supporting layer
10549015, Sep 24 2014 Sofradim Production Method for preparing an anti-adhesion barrier film
10646321, Jan 25 2016 Sofradim Production Prosthesis for hernia repair
10653508, Sep 29 2014 Sofradim Production Textile-based prosthesis for treatment of inguinal hernia
10653824, May 25 2012 Lockheed Martin Corporation Two-dimensional materials and uses thereof
10660741, Apr 24 2015 Sofradim Production Prosthesis for supporting a breast structure
10675137, May 02 2017 Sofradim Production Prosthesis for inguinal hernia repair
10682215, Oct 21 2016 Sofradim Production Method for forming a mesh having a barbed suture attached thereto and the mesh thus obtained
10696554, Aug 06 2015 Lockheed Martin Corporation Nanoparticle modification and perforation of graphene
10709538, Jul 13 2011 Sofradim Production Umbilical hernia prosthesis
10743976, Jun 19 2015 Sofradim Production; Covidien LP Synthetic prosthesis comprising a knit and a non porous film and method for forming same
10745835, Dec 05 2014 Sofradim Production Prosthetic porous knit
10751195, Oct 16 2014 JMEA Corporation Coiling implantable prostheses
10765526, Jul 07 2007 JMEA Corporation Disk fusion implant
10786232, Jan 25 2006 The Children's Medical Center Corporation Methods and procedures for ligament repair
10786238, Jan 25 2006 The Children's Medical Center Corporation Methods and procedures for ligament repair
10786239, Jan 25 2006 THE CHILDREN S MEDICAL CENTER CORPORATION Methods and procedures for ligament repair
10815345, Feb 17 2015 Sofradim Production Method for preparing a chitosan-based matrix comprising a fiber reinforcement member
10842914, Feb 01 2013 The Children's Medical Center Corporation Collagen scaffolds
10865505, Sep 04 2009 Sofradim Production Gripping fabric coated with a bioresorbable impenetrable layer
10980919, Apr 14 2016 Lockheed Martin Corporation Methods for in vivo and in vitro use of graphene and other two-dimensional materials
10981120, Apr 14 2016 Lockheed Martin Corporation Selective interfacial mitigation of graphene defects
11039912, Jul 13 2011 Sofradim Production Umbilical hernia prosthesis
11052230, Nov 08 2016 W. L. Gore & Associates, Inc.; W L GORE & ASSOCIATES, INC Implantable encapsulation devices
11076845, Jan 25 2006 The Children's Medical Center Corporation Methods and procedures for ligament repair
11076846, Jan 25 2006 The Children's Medical Center Corporation Methods and procedures for ligament repair
11266489, Dec 29 2011 Sofradim Production Barbed prosthetic knit and hernia repair mesh made therefrom as well as process for making said prosthetic knit
11291536, Sep 29 2014 Sofradim Production Whale concept-folding mesh for TIPP procedure for inguinal hernia
11304790, Jun 07 2013 Sofradim Production Textile-based prothesis for laparoscopic surgery
11331198, Oct 16 2014 JMEA Corporation Coiling implantable prostheses
11359313, Dec 05 2014 Sofradim Production Prosthetic porous knit
11389282, Jan 25 2016 Sofradim Production Prosthesis for hernia repair
11439498, Apr 24 2015 Sofradim Production Prosthesis for supporting a breast structure
11471256, Dec 29 2011 Sofradim Production Prosthesis for inguinal hernia
11471257, Nov 16 2018 Sofradim Production Implants suitable for soft tissue repair
11484578, Feb 01 2012 Rhode Island Hospital Biomaterial for articular cartilage maintenance and treatment of arthritis
11589974, Sep 29 2014 Sofradim Production Textile-based prosthesis for treatment of inguinal hernia
11612472, Mar 16 2011 Sofradim Production Prosthesis comprising a three-dimensional and openworked knit
11622845, Jun 07 2013 Sofradim Production Textile-based prothesis for laparoscopic surgery
11672636, May 02 2017 Sofradim Production Prosthesis for inguinal hernia repair
11672673, Oct 16 2014 JMEA Corporation Coiling implantable prostheses and methods for implanting
11696819, Oct 21 2016 Sofradim Production Method for forming a mesh having a barbed suture attached thereto and the mesh thus obtained
11713526, Dec 05 2014 Sofradim Production Prosthetic porous knit
11723558, Nov 03 2016 Arizona Board of Regents on Behalf of the University of Arizona Encapsulation device systems with oxygen sensors with or without exogenous oxygen delivery
11746318, Nov 03 2016 Arizona Board of Regents on Behalf of the University of Arizona Methods and systems for real-time assessment of cells in encapsulation devices pre-and post-transplantation
11806440, Feb 02 2017 NFS IP HOLDINGS, LLC Methods of improving bone-soft tissue healing using electrospun fibers
11826242, Jun 19 2015 Sofradim Production Synthetic prosthesis comprising a knit and a non porous film and method for forming same
11826489, Feb 01 2013 The Children's Medical Center Corporation Collagen scaffolds
11839696, Feb 01 2013 The Children's Medical Center Corporation Collagen scaffolds
11903807, Jul 13 2011 Sofradim Production Umbilical hernia prosthesis
6017366, Apr 18 1997 W L GORE & ASSOCIATES, INC Resorbable interposition arthroplasty implant
6383199, Aug 25 1993 COOPERSURGICAL, INC Devices for investing within ligaments for retracting and reinforcing the same
6398808, Jun 15 1999 Boston Scientific Scimed, Inc Localized delivery of genetic information from biostable materials
6840962, May 01 1995 Massachusetts Institute of Technology; Children's Medical Center Corporation Tissue engineered tendons and ligaments
7160333, Aug 04 2000 Depuy Synthes Products, LLC Reinforced small intestinal submucosa
7163563, Jul 16 2001 Depuy Synthes Products, LLC Unitary surgical device and method
7201917, Jul 16 2001 Depuy Synthes Products, LLC Porous delivery scaffold and method
7354627, Dec 22 2004 DEPUY PRODUCTS, INC Method for organizing the assembly of collagen fibers and compositions formed therefrom
7513866, Oct 29 2004 Depuy Synthes Products, LLC Intestine processing device and associated method
7569233, May 04 2004 Depuy Synthes Products, LLC Hybrid biologic-synthetic bioabsorbable scaffolds
7595062, Jul 28 2005 Depuy Synthes Products, LLC Joint resurfacing orthopaedic implant and associated method
7700747, Jan 31 2001 Seikagaku Corporation Crosslinked polysaccharide sponge
7799089, Aug 04 2000 Depuy Synthes Products, LLC Reinforced small intestinal submucosa
7819918, Jul 16 2001 Depuy Synthes Products, LLC Implantable tissue repair device
7871440, Dec 11 2006 Depuy Synthes Products, LLC Unitary surgical device and method
7893225, Jan 31 2001 Seikagaku Corporation Crosslinked polysaccharide sponge
7914579, May 01 1995 Children's Medical Center Corporation; Massachusetts Institute of Technology Tissue engineered tendons and ligaments
7914808, Jul 16 2001 Depuy Synthes Products, LLC Hybrid biologic/synthetic porous extracellular matrix scaffolds
7951936, Jan 31 2001 Seikagaku Corporation Crosslinked polysaccharide sponge
8012205, Jul 16 2001 Depuy Synthes Products, LLC Cartilage repair and regeneration device
8025896, Jul 16 2001 Depuy Synthes Products, LLC Porous extracellular matrix scaffold and method
8092529, Jul 16 2001 Depuy Synthes Products, LLC Meniscus regeneration device
8172901, Mar 20 2007 Allergan, Inc Prosthetic device and method of manufacturing the same
8337537, Jul 16 2001 Depuy Synthes Products, LLC Device from naturally occurring biologically derived materials
8366787, Aug 04 2000 Depuy Synthes Products, LLC Hybrid biologic-synthetic bioabsorbable scaffolds
8486143, May 22 2009 SOFT TISSUE REGNERATION, INC Mechanically competent scaffold for ligament and tendon regeneration
8536317, Jan 31 2001 Seikagaku Corporation Crosslinked polysaccharide sponge
8545927, May 10 2010 University of Connecticut Lactoferrin-based biomaterials for tissue regeneration and drug delivery
8614189, Sep 24 2008 University of Connecticut Carbon nanotube composite scaffolds for bone tissue engineering
8642735, Jun 22 1999 Children's Medical Center Corporation Biologic replacement for fibrin clot
8696753, Jul 07 2007 JMEA Corporation Disk fusion implant
8758437, May 22 2009 Soft Tissue Regeneration, Inc. Mechanically competent scaffold for ligament and tendon regeneration
8945218, Mar 24 2000 Drexel University Ligament and tendon replacement constructs and methods for production and use thereof
9017711, Apr 28 2011 Warsaw Orthopedic, Inc Soft tissue wrap
9060854, Mar 20 2007 Allergan, Inc. Prosthetic device and method of manufacturing the same
9180223, May 10 2012 The Trustees of the Stevens Institute of Technology Biphasic osteochondral scaffold for reconstruction of articular cartilage
9242026, Jun 27 2008 Sofradim Production Biosynthetic implant for soft tissue repair
9308068, Dec 03 2007 Sofradim Production Implant for parastomal hernia
9308242, Sep 28 2006 CHILDREN S MEDICAL CENTER CORPORATION Methods and products for tissue repair
9339369, May 09 2006 STOUT MEDICAL GROUP, L P Reinforced biological tissue
9387280, Sep 05 2008 SYNOVIS LIFE TECHNOLOGIES, INC Device for soft tissue repair or replacement
9445883, Dec 29 2011 Sofradim Production Barbed prosthetic knit and hernia repair mesh made therefrom as well as process for making said prosthetic knit
9499927, Sep 25 2012 Sofradim Production Method for producing a prosthesis for reinforcing the abdominal wall
9526603, Sep 30 2011 Sofradim Production Reversible stiffening of light weight mesh
9554887, Mar 16 2011 Sofradim Production Prosthesis comprising a three-dimensional and openworked knit
9610546, Mar 12 2014 Lockheed Martin Corporation Separation membranes formed from perforated graphene and methods for use thereof
9622843, Jul 13 2011 Sofradim Production Umbilical hernia prosthesis
9649718, Jan 31 2014 Lockheed Martin Corporation Methods for perforating multi-layer graphene through ion bombardment
9744617, Jan 31 2014 Lockheed Martin Corporation Methods for perforating multi-layer graphene through ion bombardment
9750837, Sep 25 2012 Sofradim Production Haemostatic patch and method of preparation
9757495, Feb 01 2013 CHILDREN S MEDICAL CENTER CORPORATION; THE CHILDREN S MEDICAL CENTER CORPORATION Collagen scaffolds
9833748, Aug 25 2010 Lockheed Martin Corporation Perforated graphene deionization or desalination
9834809, Feb 28 2014 Lockheed Martin Corporation Syringe for obtaining nano-sized materials for selective assays and related methods of use
9839505, Sep 25 2012 Sofradim Production Prosthesis comprising a mesh and a strengthening means
9844757, Mar 12 2014 Lockheed Martin Corporation Separation membranes formed from perforated graphene and methods for use thereof
9849213, Sep 28 2006 Children's Medical Center Corporation Methods and products for tissue repair
9870895, Jan 31 2014 Lockheed Martin Corporation Methods for perforating two-dimensional materials using a broad ion field
9877820, Sep 29 2014 Sofradim Production Textile-based prosthesis for treatment of inguinal hernia
9901457, Oct 16 2014 JMEA Corporation Coiling implantable prostheses
9931198, Apr 24 2015 Sofradim Production Prosthesis for supporting a breast structure
9932695, Dec 05 2014 Sofradim Production Prosthetic porous knit
9980802, Jul 13 2011 Sofradim Production Umbilical hernia prosthesis
Patent Priority Assignee Title
3366440,
3797047,
4127902, Jul 17 1974 TRANQUIL PROSPECTS, LTD , A COMPANY OF THE BRITISH VIRGIN ISLANDS Structure suitable for in vivo implantation
4320201, Sep 02 1980 Firma Carl Freudenberg Method for making collagen sponge for medical and cosmetic uses
4614794, Oct 04 1983 Johnson & Johnson Protein/polysaccharide complexes
4787900, Apr 19 1982 Massachusetts Institute of Technology Process for forming multilayer bioreplaceable blood vessel prosthesis
4942875, Mar 03 1986 American Cyanamid Company Surgical repair device having absorbable and nonabsorbable components
5171273, Jan 13 1989 University of Medicine and Dentistry of New Jersey Synthetic collagen orthopaedic structures such as grafts, tendons and other structures
5263983, Mar 09 1988 OLYMPUS TERUMO BIOMATERIALS CORPORATION Medical material and prosthetic skin in which cells can invade
5263984, Jul 20 1987 REGEN BIOLOGICS, INC Prosthetic ligaments
CA2092344,
EP194192A1,
EP241252A2,
EP561710,
EP274898,
WO8500511,
WO8806872,
WO9000060,
WO9203988,
WO9409720,
/
Executed onAssignorAssigneeConveyanceFrameReelDoc
Jun 07 1995Johnson & Johnson Medical, Inc.(assignment on the face of the patent)
Date Maintenance Fee Events
Jun 19 2000M183: Payment of Maintenance Fee, 4th Year, Large Entity.
Jun 29 2004M1552: Payment of Maintenance Fee, 8th Year, Large Entity.
Jul 08 2008M1553: Payment of Maintenance Fee, 12th Year, Large Entity.


Date Maintenance Schedule
Jan 21 20004 years fee payment window open
Jul 21 20006 months grace period start (w surcharge)
Jan 21 2001patent expiry (for year 4)
Jan 21 20032 years to revive unintentionally abandoned end. (for year 4)
Jan 21 20048 years fee payment window open
Jul 21 20046 months grace period start (w surcharge)
Jan 21 2005patent expiry (for year 8)
Jan 21 20072 years to revive unintentionally abandoned end. (for year 8)
Jan 21 200812 years fee payment window open
Jul 21 20086 months grace period start (w surcharge)
Jan 21 2009patent expiry (for year 12)
Jan 21 20112 years to revive unintentionally abandoned end. (for year 12)